Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Parkland Health Center-Bonne Terre — Bonne Terre, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Parkland Health Center - Farmington — Farmington, Missouri
- Freeman Health System — Joplin, Missouri
- Sainte Genevieve County Memorial Hospital — Sainte Genevieve, Missouri
- Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Missouri: - Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Missouri: - Saint Louis Cancer and Breast Institute-Ballwin — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
- Southeast Cancer Center — Cape Girardeau, Missouri
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Missouri: - University of Missouri Children's Hospital — Columbia, Missouri
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Missouri: - Mosaic Life Care at Saint Joseph - Medical Center — Saint Joseph, Missouri
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, th…
Sponsor: Black Diamond Therapeutics, Inc.
NCT ID: NCT07326566
Sites in Missouri: - Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Missouri: - Washington University School of Medicine in St. Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Missouri: - Washington University in St. Louis — St Louis, Missouri
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Missouri: - St. Louis Children's Hospital — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Missouri: - Cardinal Glennon Children's Medical Center — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Missouri: - St. Louis Children's Hospital Washington University in St. Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Sponsor: Duke University
NCT ID: NCT06069726
Sites in Missouri: - Saint Luke's Cancer Institute — Kansas City, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The stud…
Sponsor: Washington University School of Medicine
NCT ID: NCT07392957
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri